EXHIBIT 1

1) Spleen

Donor: *BALBk ♀*
Age at 1st injection: *12 Weeks*
Immunogen: *NTC + 10-12h P₂₀A₃₃₃*

	Date	Cell#	application	adjuvant	FACS-result	comments
Injections:		*bc 9951*			*87% CD69*	
		↳NTC		*no*	*95% OKT3 (6h)*	
		5·10⁶	*i·p·*		*64% TRAP*	
			i·p·	*no*	*83% OKT3⁺; 47% TRAP⁺ (12h)*	
		" 9951			*94% OKT3⁺; 66% TRAP⁺ (12h)*	
		bc.~~REG~~	*i·p·*			
		↳NTC	*i·p·*			
		10 ⁷8894	*i·p·*			

spleen cell#

2) Myeloma

Cell line: *P3x63 Ag8.653*   Density: % dead
Medium: *R10F⁻ Ⓗ*
Thawed aliquot from:

3) Fusion

Myeloma / spleen cell ratio:
Fusion medium:
PEG lot:
Protocol:

4) Selection

Percent of fusion seeded:
Density seeded: U96 F96
Selection medium:
Serum lot:
Azaserin/Hyp. lot: Aza final: Hyp. final:
First hybridomas grow:

Myeloma-spleen-fusion   No.: Ba-1 **[A]**   Date:

1) Spleen
   Donor: BALB/C ♀
   Age at 1st injection: 12 Weeks
   Immunogen: NTC + 10-12 h $P_{20}A_{333}$

[D]	Date	Cell#	application	adjuvant	FACS-result	comments
Injections:		bc9951			87% CD69	
	↳ NTC				95% OKT3 (6 h)	
	5×10^6		i.p.	no	64% TRAP	
	:	"	i.p.	no	89% OKT3$^+$;47% TRAP$^+$ (12 h)	
		bc9951	i.p.	"	94% OKT3$^+$;66% TRAP$^+$ (12 h)	
		889	i.p.	"		
		↳ NTC				
		10^7 889	i.p.	"		

spleen cell#

2) Myeloma

   Cell line: P3X63Ag8.653   Density   %dead
   Medium: R10F⁻ H
   Thawed aliquot from:

3) Fusion

   Myeloma/spleen cell ration:
   Fusion medium:
   PEG lot:
   Protocol:

4) Selection

   Percent of fusion seeded
   Density seeded: U96/F96 **[H]**
   Selection medium:
   Serum lot:
   Azaserin/Hyp. lot: Aza final: Hyp. final:
   First hybridomas grow